Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SB-751689 dose-ranging study in postmenopausal osteoporosis
2006-006015-72Phase 2Terminated
- Sponsor
- GSK
- Start
- Feb 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ronacaleret in postmenopausal osteoporosis (4 arms), sponsored by GSK. Primary endpoint: Percent change from baseline in lumbar spine bone mineral density at Month 12. Started Feb 2007; status: terminated.
02
Drugs
ronacaleret
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on 2006-006015-72.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006015-72.